Jasmin Beate Kuemmerle-Deschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5442099/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology, 2022, 61, 3082-3092.	1.9	12
2	Effective <i>ex vivo</i> inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. Rheumatology, 2022, 61, e299-e313.	1.9	11
3	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases,	0.9	38
4	Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?. Journal of Clinical Medicine, 2021, 10, 128.	2.4	44
5	CAPS bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-9.	0.0	0
6	COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment. Journal of Clinical Medicine, 2021, 10, 605.	2.4	13
7	Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood. Frontiers in Immunology, 2021, 12, 516427.	4.8	7
8	Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open, 2021, 7, e001663.	3.8	11
9	Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants. Pediatric Rheumatology, 2021, 19, 142.	2.1	5
10	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. Journal of Experimental Medicine, 2021, 218, .	8.5	33
11	Colchicine Effectiveness and Safety in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis. Frontiers in Pediatrics, 2021, 9, 759664.	1.9	13
12	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‣abel, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
13	Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open, 2020, 6, e001227.	3.8	21
14	New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Rheumatology, 2020, 59, 3259-3263.	1.9	23
15	Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatric Rheumatology, 2020, 18, 17.	2.1	41
16	Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Longâ€Term Safety Data from the German <scp>BIKER</scp> Registry. ACR Open Rheumatology, 2020, 2, 37-47.	2.1	19
17	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
18	Rapid and Sustained Longâ€Term Efficacy and Safety of Canakinumab in Patients With Cryopyrinâ€Associated Periodic Syndrome Ages Five Years and Younger. Arthritis and Rheumatology, 2019, 71, 1955-1963.	5.6	34

#	Article	IF	CITATIONS
19	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
20	Cryopyrin-Associated Periodic Syndromes (CAPS). , 2019, , 347-365.		2
21	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
22	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
23	Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults. Pediatric Rheumatology, 2018, 16, 81.	2.1	14
24	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
25	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
26	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.9	175
27	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	1.9	84
28	Brief Report: Clinical and Molecular Phenotypes of Lowâ€Penetrance Variants of <i><scp>NLRP</scp>3</i> : Diagnostic and Therapeutic Challenges. Arthritis and Rheumatology, 2017, 69, 2233-2240.	5.6	68
29	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor–Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	3.4	75
30	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
31	Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology, 2017, 56, 1484-1491.	1.9	52
32	Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Research and Therapy, 2016, 18, 272.	3.5	68
33	<i>NLRP3</i> A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms. Journal of Rheumatology, 2016, 43, 1101-1106.	2.0	22
34	Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes. Journal of Innate Immunity, 2016, 8, 493-506.	3.8	14
35	Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply. Rheumatology, 2016, 55, 1340.1-1341.	1.9	0
36	Brief Report: Severe Inflammation Following Vaccination Against <i>Streptococcus pneumoniae</i> in Patients With Cryopyrinâ€Associated Periodic Syndromes. Arthritis and Rheumatology, 2016, 68, 516-520.	5.6	42

#	Article	IF	CITATIONS
37	Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology, 2016, 55, 689-696.	1.9	55
38	Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Annals of the Rheumatic Diseases, 2016, 75, 958-964.	0.9	169
39	Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. Pediatric Rheumatology, 2015, 13, 43.	2.1	42
40	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
41	A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clinical Immunology, 2015, 157, 56-64.	3.2	32
42	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.9	145
43	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.9	239
44	CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease. Seminars in Immunopathology, 2015, 37, 377-385.	6.1	115
45	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120
46	Challenges in Diagnosing Muckleâ€Wells Syndrome: Identifying Two Distinct Phenotypes. Arthritis Care and Research, 2014, 66, 765-772.	3.4	17
47	Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry. Orphanet Journal of Rare Diseases, 2013, 8, 139.	2.7	11
48	Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Research and Therapy, 2013, 15, R64.	3.5	63
49	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
50	Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology, 2013, 147, 242-275.	3.2	75
51	Hearing loss in Muckleâ€Wells syndrome. Arthritis and Rheumatism, 2013, 65, 824-831.	6.7	59
52	Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 315-329.	2.7	46
53	Progressive familial hearing loss in Muckle-Wells syndrome. Acta Oto-Laryngologica, 2012, 132, 756-762.	0.9	19
54	Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Research and Therapy, 2011, 13, R34.	3.5	111

#	Article	IF	CITATIONS
55	B cell depletion for autoimmune diseases in paediatric patients. Clinical Rheumatology, 2011, 30, 87-97.	2.2	44
56	NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Research and Therapy, 2011, 13, R196.	3.5	51
57	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research and Therapy, 2011, 13, R202.	3.5	106
58	Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis and Rheumatism, 2011, 63, 840-849.	6.7	147
59	Impaired suppression of synovial fluid CD4+CD25â^' T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis and Rheumatism, 2011, 63, 3153-3162.	6.7	70
60	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70
61	MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases, 2011, 70, 2075-2081.	0.9	57
62	Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology, 2011, 50, 184-188.	1.9	73
63	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the Rheumatic Diseases, 2011, 70, 2095-2102.	0.9	182
64	Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics: Targets and Therapy, 2009, 2, 865.	3.2	13
65	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	27.0	754
66	MRI Findings in Deep and Generalized Morphea (Localized Scleroderma). American Journal of Roentgenology, 2008, 190, 32-39.	2.2	82
67	Adalimumab in the therapy of uveitis in childhood. British Journal of Ophthalmology, 2007, 91, 319-324.	3.9	263
68	Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatology International, 2007, 28, 153-156.	3.0	22